ALT · Altimmune, Inc. · Executive Compensation
Market Cap
$673.03M
Shares
194.52M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vipin K. Garg | Chief Executive Officer | $1,434,401 |
| Scott Harris | Chief Medical Officer | $670,183 |
| Scot Roberts | Chief Scientific Officer | $627,974 |
| William Brown | Chief Financial Officer | $622,106 |
| Sybil Tasker | M.D., MPH Former Chief Medical Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Vipin K. Garg | Chief Executive Officer | $814,647 |
| William Brown | Chief Financial Officer | $624,347 |
| Scot Roberts | Chief Scientific Officer | $448,261 |
| Scott Harris | Chief Medical Officer | $382,908 |
| Sybil Tasker | M.D., MPH Former Chief Medical Officer | $356,515 |
| William Enright | Former Chief Executive Officer | — |
| Elizabeth A. Czerepak | Former Chief Financial Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Vipin K. Garg | Chief Executive Officer | $2,189,964 |
| William Enright | Former Chief Executive Officer | $637,706 |
| Sybil Tasker | Former Chief Medical Officer | $546,331 |
| William Brown | Chief Financial Officer | $216,000 |
| Elizabeth A. Czerepak | Former Chief Financial Officer | $131,999 |
| Scott Harris | Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jerry Durso | President and Chief Executive Officer | Appointed | 2025-12-01 |
| Jerome Durso | President and Chief Executive Officer | Appointed | 2025-12-01 |
| Christophe Arbet-Engels, MD, PhD | Chief Medical Officer | Appointed | 2025-10-03 |
| Teri Lawver | Board of Directors | Appointed | 2025-02-27 |
| Jerry Durso | Board of Directors | Appointed | 2025-02-27 |
| Jerome Durso | director of the Board | Appointed | 2025-02-25 |
| Teri Lawver | director of the Board | Appointed | 2025-02-25 |
Key facts
CIK
1326190
CUSIP
02155H200
13F (30d)
142 filings
142 filers
Visit website
Investor relations